References
- Forbes: How the staggering cost of inventing new drugs is shaping the future of medicine. www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new-drugs-is-shaping-the-future-of-medicine/.
- Hay M Thomas DW Craighead JL Economides C Rosenthal J . Clinical development success rates for investigational drugs. Nat. Biotech.32 (1), 40–51 (2014).
- US Food and Drug Administration . Novel New Drugs 2014 Summary. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM430299.pdf.
- Scholes P Stevens L Paterson M Egerton M . Translational Pharmaceutics–interactive drug development to enable rapid optimisation of drug products in early development. Presented at : American Association of Pharmaceutical Sciences (AAPS) conference. Los Angeles, CA, USA, 8–12 November 2009.
- ICH Q8 Development Pharmaceutics (EMEA/CHMP/167068/2004). www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf.
- Lin W Schueller O Patel A McDermott J Sweetnam P Scholes P . Development of a formulation design space for SLx–2101 modified release tablets to enable a flexible Phase I PK study. Presented at : Annual Exposition of the Controlled Release Society (CRS). Portland, OR, USA, 10–14 July 2010.
- McDermott J Scholes P Lin W Connor A . Approaches to rapid in vivo optimization of hydrophilic matrix tablets. In : Hydrophilic Matrix Tablets for Oral Controlled Release. TimminsPPygallSRMeliaCD ( Eds). Springer, Berlin, Germany. 205–232 (2014).
- Kane Z Shao J Christopher R et al. Utilisation of RapidFACT strategies to evaluate and develop an In vitro/in vivo correlation (IVIVC) for modified release formulations of lorcaserin HCl. Presented at : Annual Exposition of the Controlled Release Society (CRS). Edinburgh, UK, 26–29 July 2015.
- Lobo ED Argentine MD Sperry DC et al. Optimization of LY545694 Tosylate controlled release tablets through pharmacoscintigraphy. Pharm. Res.29, 2912–2925 (2012)
- McDermott J Connor A Sidhu S Mayes B Moussa A Ganga S . Rapid formulation development and clinical evaluation of enabled formulations of IDX–719. Presented at : American Association of Pharmaceutical Sciences (AAPS) Conference. San Diego, CA, USA, 2–6 November 2014.
- Whitfield N Clay C Patrick L et al. Application of Translational Pharmaceutics to reduce time, cost, and risk in the early development of inhaled drug products. Presented at : Respiratory Drug Delivery Europe. Antibes, France, 5–8 May 2015.
- McDermott J Stevens L Mair S et al. Rapid formulation development and clinical evaluation of ocular formulations of AMA0076 based upon intra-ocular pressure lowering. Presented at : American Association of Pharmaceutical Sciences (AAPS) Conference. San Diego, CA, USA, 2–6 November 2014.
- Connor A Scholes P Stevens L et al. Flexible Approaches to Incorporate Formulation Assessments and Selection into First-in-Human (FIH) Safety and Tolerability Studies. Presented at : American Association of Pharmaceutical Sciences (AAPS) Conference. San Antoinio, TX, USA, 10–14 November 2013.